SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in ...
STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has ...
March 19 (Reuters) - Japan is expected to spend around 10 trillion yen ($62.72 billion) in the second phase of its $550 ...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (BLTE) (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...
First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or ...
The next phase of India–Japan economic cooperation will be powered by collaboration between Japanese mid-sized firms (Chuken) ...
The study sought to examine the safety and tolerability of gefapixant in Japanese patients with refractory or unexplained chronic cough. A phase 3 safety and tolerability study of gefapixant conducted ...
The Standard Missile (SM)-3 Block IIA missile, pictured above launching from the Pacific Missile Range Facility in Hawaii, is jointly developed by the US and Japan. The MDA said the GPI joint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results